Luis Puig

125PUBLICATIONS
180CO-AUTHORS
Disease surveillanceApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyEpidemiological methodsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (125)

|Jul 31, 2026
Effectiveness and Safety of 40 mg Modified-Release Doxycycline for the Treatment of Hidradenitis Suppurativa: A Single-Center Retrospective Observational Study.

|Jun 02, 2026
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.

|May 26, 2026
Real-World Evidence That As-Needed Dosing with Bimekizumab in Patients with Psoriasis Is Safe and Effective over Time.

|May 21, 2026
Absolute Eczema Area and Severity Index Responses with Lebrikizumab in Patients with Moderate-to-severe Atopic Dermatitis: A Secondary Analysis of Two Phase 3 Trials.

|May 14, 2026
Treatment-associated phenotype switching between psoriasis and atopic dermatitis.

|Apr 09, 2026
Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?

Fabià Torres-Betato, Lluís Puig

Pageof 21

Frequent Collaborators

14 joint publications

Paolo Gisondi

10 joint publications

Helena Iznardo

10 joint publications

Lluís Rusiñol

9 joint publications

Tiago Torres